AKt as a therapeutic target for cancer

Mengqiu Song, Ann M. Bode, Zigang Dong, Mee Hyun Lee

Research output: Contribution to journalReview articlepeer-review

253 Scopus citations

Abstract

Many cellular processes in cancer are attributed to kinase signaling networks. V-akt murine thymoma viral oncogene homolog (AKT) plays a major role in the PI3K/AKT signaling pathways. AKT is activated by PI3K or phosphoinositide-dependent kinases (PDK) as well as growth factors, inflammation, and DNA damage. Signal transduction occurs through downstream effectors such as mTOR, glycogen synthase kinase 3 beta (GSK3β), or forkhead box protein O1 (FOXO1). The abnormal overexpression or activation of AKT has been observed in many cancers, including ovarian, lung, and pancreatic cancers, and is associated with increased cancer cell proliferation and survival. Therefore, targeting AKT could provide an important approach for cancer prevention and therapy. In this review, we discuss the rationale for targeting AKT and also provide details regarding synthetic and natural AKT-targeting compounds and their associated studies.

Original languageEnglish (US)
Pages (from-to)1019-1031
Number of pages13
JournalCancer Research
Volume79
Issue number6
DOIs
StatePublished - 2019

Bibliographical note

Funding Information:
This work was supported by grants from the NIH (CA187027, CA166011, CA196639), Key Program of Henan Province, China (grant no. 161100510300 to Z. Dong), the National Natural Science Foundation of China (NSFC81672767 to M.-H. Lee), and Henan Provincial Government, China.

Publisher Copyright:
© 2019 American Association for Cancer Research.

Keywords

  • Animals
  • Antineoplastic Agents/therapeutic use
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms/drug therapy
  • Proto-Oncogene Proteins c-akt/antagonists & inhibitors

PubMed: MeSH publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'AKt as a therapeutic target for cancer'. Together they form a unique fingerprint.

Cite this